Literature DB >> 18676587

New automated multiplex assay for bone turnover markers in osteoporosis.

Aurélie Claudon1, Philippe Vergnaud, Cécile Valverde, Anita Mayr, Ursula Klause, Patrick Garnero.   

Abstract

BACKGROUND: Serum C-terminal cross-linked telopeptide of type I collagen (CTX-I), N-terminal propeptide of type I collagen (PINP), and osteocalcin (OC) are among the most sensitive bone turnover markers for evaluating osteoporosis. Each marker is currently measured individually by manual or automated immunoassays that are time consuming and require substantial sample volume. We evaluated the performance characteristics of a novel, fully automated, protein-array chip system that allows the simultaneous measurement of CTX-I, PINP, OC, and intact parathyroid hormone (PTH) in 20 microL of serum.
METHODS: We measured CTX-I, PINP, OC, and PTH using multiplex and corresponding automated single assays in 157 healthy premenopausal women, 74 healthy men, and 56 postmenopausal osteoporotic women before and 6 months after treatment with oral ibandronate (150 mg/month).
RESULTS: Within- and between-run CVs of the multiplex assay were similar to those of single measurement assays (<10% for all markers), whereas the limit of quantification was lower, except for OC. Multiplex values highly correlated (r > 0.93, P < 0.0001 for all markers) with the corresponding single assays, and measured concentrations were comparable. After 6 months of ibandronate, CTX-I, PINP, and OC decreased by a median of 48%, 63%, and 52%, respectively (P < 0.0001 for all 3 markers), magnitudes similar to those of the corresponding single assays.
CONCLUSIONS: The automated protein-array chip demonstrated similar analytical precision, improved analytical sensitivity, and comparable measured concentrations to those of single assays. The multiplex assay should be useful for assessing bone metabolism in large clinical studies, particularly when sample volume is limited.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676587     DOI: 10.1373/clinchem.2008.105866

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  18 in total

1.  Successes achieved and challenges ahead in translating biomarkers into clinical applications.

Authors:  Greg Tesch; Shashi Amur; John T Schousboe; Jeffrey N Siegel; Lawrence J Lesko; Jane P F Bai
Journal:  AAPS J       Date:  2010-03-16       Impact factor: 4.009

Review 2.  Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

Authors:  John T Schousboe; Douglas C Bauer
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

Review 3.  Bone markers in osteoporosis.

Authors:  Patrick Garnero
Journal:  Curr Osteoporos Rep       Date:  2009-09       Impact factor: 5.096

4.  Severe nutritional iron-deficiency anaemia has a negative effect on some bone turnover biomarkers in rats.

Authors:  Javier Díaz-Castro; Mercedes Ramírez López-Frías; Margarita S Campos; Magdalena López-Frías; María J M Alférez; Teresa Nestares; María L Ojeda; Inmaculada López-Aliaga
Journal:  Eur J Nutr       Date:  2011-06-07       Impact factor: 5.614

Review 5.  Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing.

Authors:  Marlon O Coulibaly; Debra L Sietsema; Travis A Burgers; Jim Mason; Bart O Williams; Clifford B Jones
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2010       Impact factor: 1.807

6.  Bioluminescence imaging correlates with tumor serum marker, organ weights, histology, and human DNA levels during treatment of orthotopic tumor xenografts with antibodies.

Authors:  Thomas Poeschinger; Anja Renner; Thomas Weber; Werner Scheuer
Journal:  Mol Imaging Biol       Date:  2013-02       Impact factor: 3.488

7.  Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study.

Authors:  Douglas C Bauer; Patrick Garnero; Stephanie L Harrison; Jane A Cauley; Richard Eastell; Kris E Ensrud; Eric Orwoll
Journal:  J Bone Miner Res       Date:  2009-12       Impact factor: 6.741

Review 8.  Bone turnover markers: understanding their value in clinical trials and clinical practice.

Authors:  R Civitelli; R Armamento-Villareal; N Napoli
Journal:  Osteoporos Int       Date:  2009-02-04       Impact factor: 4.507

9.  Novel multiplex technology for diagnostic characterization of rheumatoid arthritis.

Authors:  Piyanka E Chandra; Jeremy Sokolove; Berthold G Hipp; Tamsin M Lindstrom; James T Elder; John D Reveille; Heike Eberl; Ursula Klause; William H Robinson
Journal:  Arthritis Res Ther       Date:  2011-06-24       Impact factor: 5.156

10.  IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis.

Authors:  Jianmei Wang; Adam Platt; Ruchi Upmanyu; Søren Germer; Guiyuan Lei; Christina Rabe; Ryma Benayed; Andrew Kenwright; Andrew Hemmings; Mitchell Martin; Olivier Harari
Journal:  BMJ Open       Date:  2013-08-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.